Brief: Gilead And Assembly Biosciences In Partnership To Develop Next-Generation Therapeutics For Viral Diseases

Assembly Biosciences

17/10/2023 12:18

Oct 17 (Reuters) - Assembly Biosciences Inc  ASMB.O :
    * GILEAD AND ASSEMBLY BIOSCIENCES ESTABLISH PARTNERSHIP TO
DEVELOP
NEXT-GENERATION THERAPEUTICS FOR SERIOUS VIRAL DISEASES
    * ASSEMBLY BIOSCIENCES INC - ASSEMBLY BIO TO RECEIVE $100
MILLION
UPFRONT PAYMENT
    * ASSEMBLY BIOSCIENCES - COLLABORATION INCLUDES ASSEMBLY
BIO'S
CURRENT AND FUTURE PIPELINE CANDIDATES AND INCORPORATES TWO
GILEAD HERPESVIRUS PROGRAMS
    * ASSEMBLY BIOSCIENCES INC - GILEAD HAS AGREED TO PURCHASE
UP TO
29.9 PERCENT OF CO'S OUTSTANDING VOTING STOCK AT A PREMIUM
    * ASSEMBLY BIOSCIENCES- GILEAD MAY OPT-IN TO OBTAIN
EXCLUSIVE
RIGHTS FOR EACH OF CO'S CURRENT & FUTURE PROGRAMS
    * ASSEMBLY BIOSCIENCES- IF GILEAD OPTS-IN TO ANY PROGRAM, CO
TO
RECEIVE UP TO $330 MILLION PER PROGRAM IN POTENTIAL REGULATORY &
COMMERCIAL MILESTONES
    * ASSEMBLY BIOSCIENCES INC - GILEAD HAS RIGHT TO APPOINT TWO
INDIVIDUALS TO ASSEMBLY BIO'S BOARD OF DIRECTORS
    * ASSEMBLY BIOSCIENCES INC - TRANSACTION WITH ASSEMBLY BIO
IS
EXPECTED TO REDUCE GILEAD'S GAAP AND NON-GAAP 2023 EPS BY
APPROXIMATELY $0.05 - $0.07

Source text for Eikon:  ID:nBw9dFtWZa 
Further company coverage:  ASMB.O 

 ((Reuters.Briefs@thomsonreuters.com))